Do not administer by SC or IM route. Closely monitor patients for signs & symptoms of hypersensitivity during & for at least 30 min following each administration. Stop treatment if hypersensitivity or signs of intolerance occur. Can cause transient & w/o clinical symptom hypophosphataemia. Patients w/ existing hypophosphatemia risk factors & prolonged high IV Fe-dose exposure. Patients w/ hepatic dysfunction. Acute or chronic infection, history of asthma, eczema or atopic allergies. Discontinue use in patients w/ ongoing bacteraemia. Stop immediately in case of paravenous leakage. Monitoring of Fe parameters eg, serum ferritin & transferrin saturation may assist in recognition of Fe accumulation. Pregnancy & lactation. Not recommended in childn <14 yr.